Status:

NOT_YET_RECRUITING

The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes

Lead Sponsor:

The University of New South Wales

Collaborating Sponsors:

University of Melbourne

Conditions:

Dry Eye Disease (DED)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and dis...

Detailed Description

The immune system plays a pivotal role in dry eye disease (DED) pathogenesis. An increased level of several tear cytokines, chemokines, expression of HLA-DR molecules and activation of antigen present...

Eligibility Criteria

Inclusion

  • 18 years of age and above
  • Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \< 0.2 mm.

Exclusion

  • Participants currently using or with previous use of steroids, ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months.
  • Participants with systemic CsA or tacrolimus
  • Known hypersensitivity or contraindication to the study medication or any of its ingredients.
  • Active intraocular inflammation.
  • Contact lens wear or the use of contact lenses in the last 4 weeks.
  • Active eye infections or history of critical illness.
  • DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease.
  • Participants with other ocular co-morbidities and medications for glaucoma.
  • Participants with previous history of ocular surgery in the past 6 months.
  • Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance.
  • Pregnant/breastfeeding women

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2026

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06898853

Start Date

May 1 2025

End Date

September 30 2026

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

School of Optometry and Vision Science

Sudney, New South Wales, Australia, 2033